Navigation Links
NeuroVive Pharmaceutical AB Publishes 2016 Annual Report
Date:3/23/2017

LUND, Sweden, Mar 23, 2017 /PRNewswire/ --

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for 2016 is now available on the company's website www.neurovive.com

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company's strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.

NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

For investor relations and media questions, please contact:

Cecilia Hofvander
NeuroVive
Tel: +46-(0)46-275-62-21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village
SE-223 81 Lund, Sweden
Tel: +46-(0)46-275-62-20 (switchboard)
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:35 a.m. CET on March 23, 2017.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-publishes-2016-annual-report,c2221355

The following files are available for download:

http://mb.cision.com/Main/6574/2221355/646778.pdf

NeuroVive Pharmaceutical AB publishes 2016 Annual report

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurovive-pharmaceutical-ab-publishes-2016-annual-report-300428340.html


'/>"/>
SOURCE NeuroVive Pharmaceutical
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB
2. NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma
3. NeuroVive Redirects Research Resources From Asian Subsidiary to Parent
4. NeuroVive Signs Mitochondrial Medicine Research Agreement With US key Opinion Leader
5. NeuroVive Signs Collaboration Agreement With Karolinska Institutet
6. Update - Ampio Pharmaceuticals Provides Corporate Update
7. China Pharmaceutical Packaging Industry Report, 2016-2021
8. Global Pharmaceutical Packaging Market to Reach $129.8 Billion by 2025 - Rising Demand for Primary Pharmaceutical Packaging in Emerging Markets - Research and Markets
9. Imprimis Pharmaceuticals to Raise $3.1 Million in Registered Direct Offering
10. InDex Pharmaceuticals Concludes Well Attended Investigators Meeting for the Phase IIb Study Conduct
11. Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
Breaking Medicine Technology:
(Date:7/26/2017)... , ... July 26, 2017 , ... An inventor from ... and I haven’t yet seen an effective and dignified way to keep leeches in ... the LEECH CUP." , This invention provides an effective way to keep a leech ...
(Date:7/26/2017)... Ca (PRWEB) , ... July 26, 2017 , ... A ... lyophilization processes. Inconsistent results freeze drying samples and a lengthy freeze dry cycle are ... webinar will discuss freeze drying techniques, as well as new accessories and advancements in ...
(Date:7/26/2017)... ... July 26, 2017 , ... GTB ... cloud ; today announced the availability of its latest data protection solution Crypt-n-Chive. ... control console for Data Discovery, Classification, Encryption and Digital Rights Management; GTB Crypt-n-Chive ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and ... from April 1, 2017 to June 30, 2017. Iso International LLC recorded unaudited ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... “Now Hiring!” ... St. Louis, Missouri. The company has achieved record-breaking sales for over 30 consecutive ... the next 12 months. , The upcoming year offers excitement and growth at HDIS, ...
Breaking Medicine News(10 mins):